Prognostic biomarkers are useful in allogeneic stem cell transplantation (SCT) to predict survival and relapse outcomes. We sought to derive a prognostic scoring system, which augmented the predictive power of the disease risk index (DRI) by incorporating biomarkers and validating their significance after SCT. The outcomes of overall survival (OS) and relapse were assessed with non-relapse mortality (NRM) treated as a competing risk to relapse. Six hundred and two patients were identified through a retrospective analysis of allogeneic SCT recipients for haematological malignancy between 2000 and 2013 in a single centre. Multivariate analysis confirmed the significant predictors of OS pre-SCT were serum ferritin 41000 μg/L (hazard ratio (HR) 1.94, 95% comorbidity index (CI): 1.44-2.60), Hb o 100 g/L (HR 1.71, 95% CI: 1.27-2.30) and albumin o 30 g/L (HR 2.65, 95% CI: 1.30-5.40). In combination with DRI, these biomarkers significantly improved the Harrell's C statistic (excluding biomarkers: C = 0.60, 95% CI: 0.57-0.64; with biomarkers: C = 0.65, 95% CI: 0.62-0.69, Po 0.001). Four prognostic groups were derived at the pre-SCT time point: Group 1 (Scores 0-1, n = 180, HR = 1 (ref)), Group 2 (Scores 2-5, n = 298, HR 2.7, 95% CI: 1.8-3.9), Group 3 (Scores 6-7, n = 87, HR 4.5, 95% CI: 3.0-6.9) and Group 4 (Scores 8-10, n = 9, HR 13.4, 95% CI: 5.9-30.2). These prognostic models were also predictive of relapse and NRM and remained valid at day 100, 12 months and 24 months post SCT.
INTRODUCTION
Prognostic tools are useful in allogeneic stem cell transplantation (SCT) to predict outcomes and to guide physicians in appropriate decision-making as to whether to proceed with SCT in individual patients. The disease risk index (DRI), derived from the underlying haematological malignancy, cytogenetics for AML and myelodysplastic syndromes, and stage of disease at the time of transplant, is a validated tool, which has been used widely for prediction of survival outcomes in allogeneic SCT. 1, 2 We have independently confirmed the applicability of the DRI at our centre. 3 In addition to DRI, previous studies have shown the importance of other biomarkers in predicting survival outcomes in SCT patients. High pre-SCT serum ferritin has been shown to be associated with inferior survival likely to be moderated through non-relapse mortality (NRM) 4, 5 or increased relapse rates. 6, 7 Post allogeneic SCT, serum ferritin has also been evaluated showing that (1) patients with persistently elevated serum ferritin levels up to 5 years post transplant have an increased risk of mortality 7 and (2) serum ferritin levels of ⩾ 1000 ng/mL at 1 year post transplant were associated with chronic GvHD (cGvHD) and increased red cell transfusion requirements, and were more predictive of inferior overall survival (OS) and NRM in comparison with high serum ferritin levels detected pre-transplantation. 8 Both of these studies demonstrated a continuous decrease in serum ferritin levels with time post transplantation with median values in the normal range by 5 years. A prognostic scoring system incorporating pretransplant serum ferritin and disease risk was useful in predicting survival in patients with AML and myelodysplastic syndromes post allogeneic SCT. 9 Other pretransplant biomarkers that add to prognostic information following allogeneic SCT include C-reactive protein, albumin and platelet counts. 10, 11 These pre-SCT biomarkers add further prognostic information to the haematopoietic cell transplant comorbidity index (CI) for transplant outcomes, but any impact at post SCT time points has not been studied. In addition, it is unknown whether these biomarkers can augment the DRI for risk stratification of allogeneic SCT patients.
We sought to verify the significance of these biomarkers at the pre-SCT time point and to derive a prognostic scoring system pre-SCT and assess their validity at specific time points post SCT-Day 100 (D100), 12 months (M12) and 24 months (M24) in predicting OS, cumulative incidence of relapse (CIR) and NRM outcomes.
METHODS

Patients and biomarker assessment
We undertook a retrospective analysis in a single centre of all allogeneic SCT recipients for haematological malignancy between 2000 and 2013 inclusive. There were 602 patients identified for the study period. Full blood examination (FBE), iron studies and liver function tests (LFTs) were performed pre-SCT and D100, M12 and M24 post SCT. The pre-SCT biomarkers analysed were iron studies (serum ferritin, transferrin saturation, transferrin level, iron level and total iron-binding capacity), FBE parameters (haemoglobin (Hb), platelet count, mean corpuscular volume, white cell count and differentials) and LFTs (albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), bilirubin and lactate dehydrogenase (LDH)). The number of patients with available data for iron studies were 598, Hb and white cell count 599, platelets 595, albumin 599, ALT and ALP 598, GGT 596, bilirubin 595 and LDH 586.
DRI was calculated retrospectively using information from the Bone Marrow Transplant database. This study was approved by the Royal Melbourne Hospital Human Research Ethics Committee project number QA2014145.
Statistical analysis
Descriptive analysis was conducted to present the overall sample. Time to OS and relapse were assessed, with NRM treated as a competing risk to relapse. 12 Data were censored at last follow-up. Co-variates considered in the univariate analysis and then multivariate analysis if predictive of OS or relapse/NRM included age, gender, disease type, DRI, conditioning intensity, graft source, donor type, CMV status, GvHD prophylaxis and acute GvHD (aGvHD) and/or cGvHD, which were treated as timedependent covariates. Cox proportional hazard models were considered, with Harrell's C statistic 13, 14 used to assess the performance of each multivariate model.
The biomarkers were initially considered individually, while adjusting for potential confounders to identify the strongest predictor within the iron, FBE and LFT groups. The strongest predictors were then included in the same multivariate regression model, with manual backwards step-wise regression techniques applied to identify the independent predictors of OS or relapse/NRM. Results were reported as hazard ratios (HRs) with associated 95% confidence intervals, with Kaplan-Meier curves prepared for OS and cumulative incident curves prepared for the competing risks of relapse and NRM. The coefficients estimated for each level of each variable from the final multivariate models at each time point were then used to estimate scores (using the smallest coefficient value as reference), with a total score estimated for each patient, with statistically significant prognostic groups determined for OS and relapse/NRM, using the likelihood ratio test. Those patients relapsed or deceased before each time point (D100, M12 and M24) were omitted from the relevant models. P-values of o0.05 were considered statistically significant. Statistical analysis was performed using Stata version 12.1 (StataCorp LP, Texas, USA).
RESULTS
The characteristics of the 602 patients are listed in Table 1 . The median age of the study cohort was 49 years (± s.d. of 13). Sixty-one per cent of the patients had a related donor SCT, 34% an unrelated donor SCT and 4% cord blood SCT. The majority (62%) received myeloablative conditioning regimens, whereas 79% received a peripheral blood graft source and 16% a bone marrow graft source. The most common underlying haematological malignancy was AML in 37% of patients, followed by non-Hodgkin lymphoma (16%) and ALL (15%). DRI was low in 9%, intermediate in 62%, high in 25% and very high in 1%. Post-SCT GvHD prophylaxis was primarily with cyclosporin and methotrexate for the related and unrelated donor transplants, and mycophenolate mofetil for the cord blood transplants.
The median pre-SCT serum ferritin level was 1079 μg/L, post-SCT D100 2074 μg/L, M12 993 μg/L and M24 740 μg/L. The increase in D100 serum ferritin correlated with aGvHD occurrence (P = 0.015) but there was no significant correlation at other post-SCT time points (Supplementary Figure 1) .
Multivariate analysis showed no significant statistical effect of the co-variates of gender, disease type, graft source, donor type, conditioning intensity nor CMV status on OS. After adjusting for these potential confounding factors in multivariate analysis, the following biomarkers were found to be predictive of OS at the pre-SCT time point (strongest biomarker in each group highlighted in bold): The biomarkers found to be predictive of OS from each group were serum ferritin 41000 μg/L, Hb o100 g/L and albumin o30 g/L (Figures 1a-c), and these variables were then considered in the same model to determine whether they remained independently predictive of OS and relapse/NRM. These biomarkers remained predictive of survival outcome independent of DRI with no interaction demonstrated between pre-SCT serum ferritin levels and DRI across all models. The main causes of death in the high and low ferritin groups in comparison with the median value were progressive disease (25% vs 14%), infection (7% vs 5%) and GvHD (6% vs 5%), respectively.
Prognostic scoring models Overall survival. Upon multivariate analysis, all three pre-SCT biomarkers identified above (albumin o30 g/L, serum ferritin 41000 μg/L and Hb o 100 g/L) were found to be independently predictive of OS at the pre-SCT time point (Table 2 ). The Harrell's C statistic was significantly improved with the addition of the significant biomarkers (excluding biomarkers: C = 0.60, 95% CI: 0.57-0.64; with biomarkers: C = 0.65, 95% CI: 0.62-0.69, P o0.001).
Having a high/very high DRI level was predictive of increased mortality (HR 3.2, 95% CI: 1.7-6.1), when compared with a low DRI level. cGvHD showed a time-dependent effect in improving OS Abbreviations: BM = bone marrow; DRI = disease risk index; MA = myeloablative; MDS = myelodysplastic syndrome; NMA = non-myeloablative; PB = peripheral blood; RIC = reduced intensity conditioning.
but not when included in the predictive model at specific time points post SCT. Four prognostic groups were derived from the scores assigned to each level of the significant variables: Group 1 (Scores 0-1, n = 180, HR = 1 (ref)), Group 2 (Scores 2-5, n = 298, HR 2.7, 95% CI: 1.8-3.9), Group 3 (Scores 6-7, n = 87, HR 4.5, 95% CI: 3.0-6.9) and Group 4 (Scores 8-10, n = 9, HR 13.4, 95% CI: 5.9-30.2) ( Table 2 and Figure 2a ). Based on these prognostic groups, the survival estimates at 12 months were 91% for Group 1, 77% for Group 2, 59% for Group 3 and 17% for Group 4. At 24 months, the survival estimates were 88%, 68%, 47% and 17% for Groups 1-4, respectively (Supplementary Table 1) . Models and prognostic groups were then developed for the D100, M12 and M24 time points (Table 2 and Figures 2b-d) . At the D100 time point, pre-SCT biomarkers of albumin o30 g/L, serum ferritin 41000 μg/L and DRI remained significant for predicting survival outcomes, with the addition of aGvHD (Grades 2-4). At the M12 time point, pre-SCT biomarkers of serum ferritin 41000 μg/L and DRI remained significant predictors of inferior survival with the addition of age 460 years. At the M24 time point, only the DRI remained a significant predictor of OS outcome. These confirmed an inferior survival for patients in the higher score groups, which remained consistent across all pre-SCT and post SCT time points.
Relapse. Upon multivariate analysis, pre-SCT serum ferritin 41000 μg/L and DRI were predictive of increased relapse risk at the pre-SCT time point (Table 3) . Three prognostic scoring groups were derived: Group 1 (Score 0, n = 38, HR 1 (ref)), Group 2 (Scores 1-3, n = 448, HR 4.4, 95% CI: 1.4-13.8) and Group 3 (Score 4, n = 88, HR 7.7, 95% CI: 2.4-24.9) ( Table 3 and Figure 3a) .
At the pre-SCT time point, the CIR at 12 months for each group were (%, 95% CI): Group 1 (10.4, 1.9-30. 4 At the D100 time point, only the DRI remained a significant predictor for relapse risk (Table 3) . At the M12 time point, DRI and cGvHD were predictive of relapse risk with attenuated CIR in those with limited or extensive cGvHD. At the M24 time point, only cGvHD remained a significant predictor of CIR.
Prognostic scoring groups were derived at each time point (Table 3) and CIR curves estimated (Figures 3b-d) . These confirm an increased relapse risk with serum ferritin 41000 μg/L, higher DRI and an absence of cGvHD.
Non-relapse mortality. Upon multivariate analysis, age 460 years and Hb o 100 g/L at the pre-SCT time point were predictive of inferior NRM (Table 4) . Two prognostic scoring groups were derived: Group 1 (Score 0, n = 360, HR 1 (ref)) and Group 2 (Scores 1-2, n = 239, HR 1.8, 95% CI: 1.2-2.7) ( Table 4 and Figure 4a) .
At the pre-SCT timepoint, the NRM estimates at 12 months for each group were (%, 95% CI): Group 1 (8. At the D100 time point, age 460 years remained a significant predictor of NRM and aGvHD (Grades 2-4) ( Table 4) . At the M12 time point, pre-SCT serum ferritin 41000 μg/L and age 460 years were predictive of inferior NRM. At the M24 time point, only plateletso 50 ×10 9 /L was predictive of NRM. Prognostic scoring groups were derived at each time point (Table 4 ) and presented as cumulative incidence of NRM (Figures 4b-d) . These show an increased NRM risk with increasing age, aGvHD, serum ferritin41000 μg/L and low platelets.
DISCUSSION
In this study, we confirm the prognostic significance of pretransplant serum ferritin 41000 μg/L, low albumin o 30 g/L and low Hb o 100 g/L in survival outcomes, and that these factors add to risk stratification derived from the DRI. Importantly, these pre-SCT biomarkers maintained their significance at day 100, 12 months and 24 months post transplant with only DRI remaining significant across all time points. In addition to DRI, the absence of cGvHD increased the relapse risk. For NRM, in addition to high serum ferritin, age 460 years, aGvHD (Grades 2-4) and low platelets o 50 × 10 9 /L increased risk of NRM. There is debate concerning the relationship between high serum ferritin and survival outcome, as this could reflect the direct effect of iron on organ function or transfusional iron overload and/or comorbidities associated with pre-SCT disease status. Serum ferritin has been used as a surrogate marker for iron overload; [15] [16] [17] however, a meta-analysis of liver iron concentration studies assessed non-invasively through magnetic resonance imaging quantification pretransplantation showed no impact on survival outcomes. 18 There is a suggestion that true iron overload per se, correlating with higher serum ferritin of 42500 ng/mL (liver iron concentration~6 mg/g dry weight) pretransplantation is less important in predicting survival outcomes than the 1000-2500 ng/mL group, in which the serum ferritin more probably reflects an inflammatory state associated with disease status or comorbidity-related issues. 18 In support of this hypothesis, a study monitoring ferritin levels pre-and post transplant showed that the worst outcomes were associated with patients who had serum ferritin levels o 1000 ng/mL (low) pretransplant, who then subsequently developed a serum ferritin of ⩾ 1000 ng/mL (high) 1 year post transplant (low-high group) in comparison with the high-high group and best outcomes were seen in the high-low group. 8 These inflammatory states include concurrent infections and GvHD, but there is variable association between elevated serum ferritin and GvHD; 7, 19 thus, limiting its use as a reliable biomarker for GvHD.
As serum ferritin is an imperfect marker of true iron overload, other parameters of iron studies such as iron, transferrin, total ironbinding capacity and transferrin saturations were also assessed for survival outcomes in this study. Transferrin, transferrin saturations, iron and/or soluble transferrin receptor demonstrated predictive power for posttransplant mortality independent of other factors such as disease type, stage, conditioning regimen and C-reactive protein level. 6, 7 However, in our study, although high transferrin and total iron-binding capacity levels above median values were significant for improved survival outcomes, serum ferritin was the most significant predictor of OS. As has been demonstrated in other studies, the serum ferritin levels in our patient cohort increased at the D100 time point in comparison with pre-SCT and subsequently decreased at the later time points. We showed a correlation Abbreviations: aGvHD = acute GvHD; CI = comorbidity index; DRI = disease risk index; HR = hazard ratio; OS = overall survival; SCT = stem cell transplantation. OS scoring model at four time points-pre-SCT and post-SCT D100 (100 days), M12 (12 months) and M24 (24 months). Bold entries indicate highlighting score values. Abbreviations: cGvHD = chronic GvHD; CI = comorbidity index; CIR = cumulative incidence of relapse; DRI = disease risk index; HR = hazard ratio; SCT = stem cell transplantation. Relapse scoring model at four time points-pre-SCT and post-SCT D100 (100 days), M12 (12 months) and M24 (24 months).
between aGvHD occurrences and increased serum ferritin level at D100 with increased mortality risk. Following the acute posttransplant period (3-6 months), patients achieve transfusion dependence and remission from their primary haematological malignancies, which contribute to lower serum ferritin levels. A significant correlation between high serum ferritin levels and abnormal LFTs has also been reported. 20 High ALT, AST and GGT demonstrated significant correlation and, similarly, we found that high AST and GGT had an impact on survival outcomes but low albumin was the most significant predictor. Serum albumin is a useful prognostic indicator in multiple cancer types and is thought to either reflect the nutritional state of the patient or an inflammatory state related to the underlying disease or infections, with the latter thought to have a more important role. 21, 22 In Abbreviations: CI = comorbidity index; HR = hazard ratio; NRM = non-relapse mortality; SCT = stem cell transplantation. NRM scoring model at four time points -pre-SCT and post-SCT D100 (100 days), M12 (12 months) and M24 (24 months).
haematopoietic cell transplant studies, malnourished patients measured through body weight, body mass index and/or low arm muscle mass have inferior NRM in the early post-transplant period but the serum albumin was not correlated with outcome in these studies. 23, 24 Nevertheless, serum albumin remains an important predictor of outcomes in allogeneic stem cell transplants. 10, 11 Cytopenias pretransplant probably reflect poor marrow reserve and/or hypersplenism and previous studies have shown the prognostic values of thrombocytopenia and neutropenia. 10, [25] [26] [27] We found, however, that pre-SCT anaemia was the most predictive FBE marker rather than thrombocytopenia. Similarly, leukocytosis rather than neutropenia was predictive of inferior survival outcomes, possibly related to a heightened inflammatory state. These differences in findings could be the result of differences in the patient population studied and categorization of disease risk. In the study by Vaughn et al., 10 there was inclusion of non-malignant diseases, whereas our study only included haematological malignancies, and the disease risk grouping was dichotomized to low and high, whereas in this study, the DRI stratification was utilized.
The limitations of this study include its retrospective nature and the lack of consistent measurement of C-reactive protein pre-SCT, which would have been a useful biomarker to study as another measure of inflammatory response. The significant biomarkers identified in this study have consistently been shown to have an impact on transplant outcomes but the underlying mechanisms and interactions need to be delineated further. We aim to validate this prognostic model in a multicentre study through collaboration with other institutions or conduct it through a registry and also include haematopoietic cell transplant CI to assess whether the predictive power can be further augmented. We postulate that these biomarkers probably reflect an inflammatory state and aim to correlate transplant outcomes in our cohort with measurement of cytokine levels, such as interleukin-6 and C-reactive protein, from stored serum samples. Prospective studies are also required to assess the role of intervention aiming to optimise these adverse biomarkers, such as parenteral nutrition to improve albumin levels and phlebotomy or iron chelation to reduce high serum ferritin and to determine the optimal timing of delivery of these interventions. Although studies have shown beneficial effects of phlebotomy as early as 60 days post transplant in reducing ferritin, 20 ,28 the impact on survival or other outcomes is not known. Interventions to reduce the inflammatory state before transplant may be more beneficial but could increase the potential risk of opportunistic infections and need to be studied further.
In conclusion, our study is the first to show the predictive power of pretransplant serum ferritin, albumin and Hb in augmenting the DRI for prognostic stratification of survival outcomes. We also show that these biomarkers remain predictive even in the posttransplant time points up to 24 months, suggesting the ongoing interaction of these pretransplant biomarkers. High DRI and absence of cGvHD were the most significant predictors of relapse risk consistent with known graft-versus-leukaemia effect with concurrent GvHD. In contrast, aGvHD at D100 was predictive of inferior NRM and age 460 years had an impact on NRM at all time points pre-and post SCT other than 24 months. 
